NSCLC, metastatic 1
Invited discussant LBA43 and abstract 1201O
Date
09 Oct 2016Session
NSCLC, metastatic 1Presenters
Pasi JänneAuthors
P.A. JänneAuthor affiliations
- Thoracic Oncology, Dana-Farber Cancer Institute, 02215 - Boston/US
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
3732 - Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study
Presenter: Giorgio Scagliotti
Session: NSCLC, metastatic 1
Resources:
Abstract
Slides
2356 - Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM)
Presenter: Enriqueta Felip
Session: NSCLC, metastatic 1
Resources:
Abstract
Slides
Invited discussant LBA42_PR and abstract 1208O
Presenter: Egbert Smit
Session: NSCLC, metastatic 1
Resources:
Slides
2988 - Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)
Presenter: Luis Paz-Ares
Session: NSCLC, metastatic 1
Resources:
Abstract
Slides
3919 - Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): Final overall survival (OS) analysis
Presenter: Jean-Charles Soria
Session: NSCLC, metastatic 1
Resources:
Abstract
Slides
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.